Measures used to treat contrast-induced nephropathy: Overview of reviews

British Journal of Radiology

Volumn 86, Issue 1021, 2013, Pages

  Kwok, C S ^a   Pang, C L ^a   Yeong, J K ^a   Loke, Y K ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THEOPHYLLINE;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; INTRAVENOUS PYELOGRAPHY; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MORTALITY; RENAL REPLACEMENT THERAPY; RENOGRAPHY; SYSTEMATIC REVIEW (TOPIC); TRANSLUMINAL CORONARY ANGIOPLASTY; COMPARATIVE STUDY; DRUG TOXICITY; KIDNEY DISEASE; META ANALYSIS; PREVALENCE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ACETYLCYSTEINE; DRUG TOXICITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; PREVALENCE; RISK ASSESSMENT; SODIUM BICARBONATE; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 84871882553     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20120272     Document Type: Article

References (48)

1. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012;125:66-78.
2. Morcos SK. Contrast media-induced nephrotoxicity-questions and answers. Br J Radiol 1998;71:357-85.
3. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999;9:1602-13.
4. Kooiman J, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, et al. Meta-analysis: Serum creatinine changes following contrast enhanced CT imaging. Eur J Radiol 2012;81:2554-61.
5. Bakris G, Baber A, Jones J. Oxygen free radicals involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology 1990;175:57-60. (Pubitemid 20108540)
6. Bakris G, Lass N, Gager A. Radiocontrast medium-induced declines in kidney function: a role for oxygen free radical. Am J Physiol 1990;258:F115-20. (Pubitemid 20063077)
7. Bakris G, Lass N, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction. Kidney Int 1999;56:206-10. (Pubitemid 29300536)
8. Heyman S, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685-91. (Pubitemid 29506070)
9. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast induced nephropathy. Am J Cardiol 2006;98:5K-13K.
10. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-82. (Pubitemid 43974195)
11. Carbonell N, Sanjuan R, Blasco M, Jorda A, Miguel A. N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol 2010;63:12-19.
12. Lawlor DK, Moist L, DeRose G, Harris KA, Lovell MB, Kribs Sw, et al. Prevention of contrast-induced nephropathy in vascular surgery patients. Ann Vasc Surg 2007;21:593-7. (Pubitemid 47333064)
13. Shy KG, Cheng JJ, Kuan P. Acetylecysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8. (Pubitemid 35192860)
14. ACT Investigators. Acetylecysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography. Main results from the randomized acetylcysteine for constrast-induced nephropathy trial (ACT). Circulation 2011;124:1250-9.
15. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of constrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-34. (Pubitemid 38656299)
16. Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, Banderjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol 2007;49:1283-8. (Pubitemid 46467227)
17. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-17. (Pubitemid 46594764)
18. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007;100:781-6. (Pubitemid 47268267)
19. Saidin R, Zainudin S, Kong N, Maskon O, Saaidin N, Shah S. Intravenous sodium bicarbonate versus normal saline infusion as prophylaxis against contrast nephropathy in patients with chronic kidney disease undergoing coronary angiography or angioplasty [Abstract]. J Am Soc Nephrol 2006;17:766A.
20. Addad F, Gamra H, Jemmali M, Dridi Z, Ben Hamda K, Betbout F, et al. Acetylcysteine versus bicarbonate or combination to prevent contrast-induced nephropathy in patients with diabetes and chronic renal insufficiency: ABC contrast study. In. World Congress of Cardiology - ESC Congress 2006; 2-6 September 2006; Barcelona, Spain: P1544. Barcelona, Spain: European Society of Cardiology Congress; 2006.
21. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2003;17:1936-41.
22. Huber W, Schipek K, Ilgmann K, Page M, Hennig M, Wacker A, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-62. (Pubitemid 36561376)
23. Gandhi M, Brown P, Romanowski C, Morcos S, Campbell S, El nahas A, et al. The use of theophylline, an adenosine receptor antagonist in the prevention of contrast media induced nephrotoxicity [letter]. Br J Radiol 1992;65:838.
24. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C, et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-9. (Pubitemid 29209299)
25. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-94. (Pubitemid 351665489)
26. Li X, Li T, Fu N, Hu Y, Cong H. Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy? A meta-analysis about this field. Int J Cardiol 2012;486-8.
27. Zhang B-C, Li W-M, Xu Y-W. High-dose statin pretreatment for the prevention of contrast-induced nephropathy a meta-analysis. Can J Cardiol 2011;27:851-8.
28. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al. Systematic review: Sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009;151:631-8.
29. Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012;60:360-70.
30. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. (Pubitemid 27341818)
31. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program]. In: Indirect treatment comparison. 1.0 edn. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2009.
32. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12. (Pubitemid 26120810)
33. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar Lam Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004;19:1803-7. (Pubitemid 38961391)
34. Lopez BL, Snyder JW, Birenbaum DS, Ma XI. N-Acetylcysteine enhances endothelium-dependent vasorelaxation in the isolated rat mesenteric artery. Ann Emerg Med 1998;32:405-10. (Pubitemid 28495767)
35. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radio-contrast-induced nephropathy. Invest Radiol 2010;45:188-95.
36. Arend LJ, Barkris GL, Burnett JC JR, Megerian C, SPielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987;110:406-11. (Pubitemid 18029904)
37. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
38. Oldroyd SD, Fang L, Haylor JL, Yates, MS El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rate kidney. Clin Sci (Lond) 2000;98:303-11. (Pubitemid 30145237)
39. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J 2003;24:225-48. (Pubitemid 36207079)
40. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112. (Pubitemid 36694752)
41. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010;105:288-92.
42. Acikel S, Muderrisoglu H, Yidirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 2010;21:750-5.
43. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ. Prevention of radiocontrast medium-inducted nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J 2008;155:499.e1-8.
44. Zhou X, Jin YZZ, Wang Q. Efficacy of high dose atorvastatin on preventing contrast nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:394-96.
45. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20mg versus 80mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:519-24.
46. Lin J, Hong L-R, Qiu Y. [Clinical research of atorvastatin on preventing contrast-induced nephropathy in patients underwent coronary artery CTA]. Clin Med Eng 2010;17:48-50.
47. Hua X-P, Wu R-X, Yang Y, Cao Z, Chen B. [Prevention of contrast-induced nephropathy using high-dose atorvastin in patients with coronary heart disease undergoing elective percutaneous coronary intervention] Milit Med J South China 2010;24:448-51.
48. Fischereder M. Use of intravenous sodium bicarbonate might increase the risk of contrast nephropathy. Nat Clin Pract Nephrol 2008;4:296-7. (Pubitemid 351769330)